Bevacizumab angiogenesis inhibitors

Avastin



Trial Studied treatment Control Patients Size Study type Results NCT

Advanced breast cancer (metastatic) - angiogenesis inhibitors in all type of patients - angiogenesis inhibitors in first line therapy - angiogenesis inhibitors in second line therapy

AVF2119g (Miller) cape, 2005bevacizumab + capecitabinecapecitabine462 (232/230) Confirmatory -
RIBBON-I (Robert) on top capecitabine, 2009bevacizumab + capecitabinecapecitabineNA
AVADO (Miles) 7.5mg, 2010bevacizumab + docetaxeldocetaxel489 (248/241)
AVADO (Miles) 15mg , 2009bevacizumab + docetaxeldocetaxelNA
Burstein, 2005bevacizumab + methotrexatemethotrexateNA
Martin bevacizumab, 2011bevacizumab + paclitaxelpaclitaxelNA
E2100 (Miller), 2007bevacizumab + taxanestaxanes722 (368/354) Confirmatory - NCT00028990
RIBBON-I (Robert) on top Tax or anthra, 2009bevacizumab + taxanestaxanesNA
RIBBON-2 (Brufsky), 2009bevacizumav + CTCT aloneNA

Lung cancer (metastatic) - angiogenesis inhibitors in all type of patients

Reck, 2010bevacizumabNA
Sandler, 2006bevacizumabplatinum based CTNA
Johnson, 2004bevacizumabplatinum based CTNA
Nishio, 2009bevacizumabplatinum based CTNA
Herbst, 2007bevacizumabplatinum based CTNA
Herbst, 2011bevacizumab + erlotiniberlotinib aloneNA

Renal-cell carcinoma (advanced) - angiogenesis inhibitors in all type of patients

Yang, 2003bevacizumabplacebo116 (76/40) Exploratory
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alpha732 (369/363)
AVOREN, 2007bevacizumab plus interferon alfainterferon alpha649 (327/322)



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons